Eisai: Citius Oncology, Inc. and Eisai Co., Ltd. Enter into Letter Agreement that Amends License Agreement to Provide for Payment Schedule to Eisai

Citius Oncology Inc. announced on March 28, 2025, Citius Oncology and Eisai Co., Ltd. entered into a letter agreement that amended the License Agreement to provide for a payment schedule to Eisai. Citius Oncology has agreed to pay Eisai on or before July 15, 2025, an aggregate amount of $2,535,317.77 and thereafter on the 15th of each of the next four months to pay Eisai $2,350,000 and make a final payment of $2,197,892.07 to Eisai on or before December 15, 2025, in each case with interest on each obligation from its original due date through the date of actual payment under the letter agreement at the rate of 2% per annum. The parties released each other from any and all claims, losses, damages, costs and expenses that arise from or related to the failure of Citius Oncology to pay the milestone payment or the other incurred costs under the License Agreement except for any claims arising out of a breach of the letter agreement. All other terms of the License Agreement remain in full force and effect.